Buy Generic Finasteride (Finpecia)

Cheap version of Generic Propecia is FINPECIA

Active substance: Finasteride
U.S. Brand: Propecia
Indian Brand: Finpecia
Made by:
Strength: 1 mg
Form release: blister with 15 tablets
Shipping time: 7 – 21 days
Best price: 0.19 USD
through request form

DescriptionHow to take?Common Side EffectsLatest New'sPhoto's

Doctor Roy – The active ingredient of the drug is Finasteride. It is used to treat baldness problems in male. Finpecia is an effective medication used in the management of hair fall in men. It helps in the treatment of male pattern baldness. The main ingredient of this drug is Finasteride that helps in reducing hair loss by preventing the conversion of testosterone into DHT. This reduces the amount of DHT in the body, which results in increased hair growth and reduced hair loss. This medicine does not affect the hair growth in other parts of the body.

The manufacturer of Finpecia – 1mg is Cipla trust company, India. You can purchase Finpecia – 1mg online also through request page on our website.

The medicine works by converting testosterone into more potent androgen dihydrotestosterone (DHT). Dihydrotestosterone is the main hormone that shrinks the hair follicle which is responsible for baldness and hair loss. As per studies conducted, the medicine works on both the hairline and crown area. However, it shows most of its effects on the crown area.

The usual recommended dose of Finpecia for the treatment of benign prostatic enlargement and hair fall is 1 tablet a day. Men are advised to contact a physician to learn more about the dosage recommendations.

Store Finpecia tablets at a cool and dry place. The tablets should be kept in a tightly closed container away from heat and moisture.

Pain in the breasts, Decreased sexual desire, Painful erections, Inability to maintain or sustain an erection.

Finpecia is not meant for treating hair fall in women.

Global Market 2025

The report covers the present scenario and the growth prospects of the global Finasteride market for 2013-2025. To calculate the market estimate, the report considers the income produced from the Finasteride market from various regions.

The scope of Global Finasteride Market will help the readers in analyzing opportunities segmented by regions North America,  Europe, Asia-Pacific, South America, Middle East & Africa. The market concentration ratio and maturity check are conducted to analyze development trends. The industry chain analysis with upstream raw material suppliers and downstream buyers of Global Finasteride Industry is covered. The sales channel, labor cost and raw materials cost is presented. The growth rate and market share for every type, applications from 2013-2019 is explained. The gross margin analysis, production, value, and import-export details of Global Finasteride Industry is presented in this study. The SWOT analysis, market status for key regions and countries like North America, Europe, Japan, China, India, and South America is studied comprehensively.

Get FREE Sample Report Copy @

The Top Finasteride Industry Players Are:

Teva Pharmaceuticals
Dr. Reddy
Accord Pharmaceuticals
Henan Topfond
Zhejiang CONBA Pharmaceutical
Shandong Renhetang Pharmaceutical
Guangdong Eashu Pharmacetica

In-depth assessment of segment and subsegment are given below

Types of Global Finasteride Market:

1 mg Tablet
5 mg Tablet

Applications of Global Finasteride Market:

Medical Uses
Prostate Enlargement
Prostate Cancer
Scalp Hair Loss
Excessive Hair Growth
Transgender Women

The competitive profile of top Global Finasteride Industry players, product portfolio, gross margin statistics, and market share for every region is explained. In the next segment, forecast analysis of Finasteride Industry is conducted to state upcoming market value and volume estimates. The analytical data which will drive market growth is estimated in detail. The positive and negative aspects of Global Finasteride industry are explained for vital decision-making study. The industry barriers and SWOT analysis of emerging Finasteride Industry players are explained. Also, analyst views, suggestion and data sources are portrayed.

Inquiry Here For Detail Report @

The Following Global Finasteride Market Questions Will Be Answered By Our Study:

The risk associated with raw material sources, cost structures and emerging competitor’s feasibility are studied. The growth percentage in the coming years, as well as Global Finasteride market segments reflecting heavy growth, are presented in the report. The sales data of players, their regional presence, suppliers, revenue structure and manufacturing process is explained. Also, import-export details and production volume is reflected in this study.

The Global Finasteride market share in revenue in USD Million is portrayed for the different product types. The industry demand, business strategies will help in understanding the workflow and development trends. The macro and microeconomic factors fueling market development are verified. The analysis of capacity, sales price, market trends and consumption status is conducted. The new product launch events, mergers & acquisitions and innovations in Global Finasteride Market are also presented in this report.

Noteworthy Offerings Of Global Finasteride Market Research Report:

The report users and industry aspirants will have complete knowledge on Global Finasteride market present status and upcoming future developments. The expected cost of products, growth trends and product value in coming years is presented. Also, the growth opportunities, profit-making ventures and successful business plans can be built efficiently. All the well-established, mid-level, as well as emerging players, can analyze the market scope, market size and growth opportunities. Detailed research on every niche region/countries offers fundamental market statistics and outlook.

The quantitative and qualitative data in this report will help you gain useful Global Finasteride industry details and future scope. The complete details like sales price analysis, market trends, raw material sources and consumer analysis is elaborated in this study.  Also, the Global Finasteride Industry distribution channels, production plants, R&D status, and raw material sources are presented. The market expansion scope, analytics and strategic view are studied.

To know More Details About Finasteride Market research Report @:


Contact Us:

Company Name: WeMailMD (WMMD)

Contact Person: Tina Sugandh



The Pill



More hair…this is the pill for that. It treats male pattern baldness, at the crown and in the middle of the scalp. You’ll see thicker hair and slower hair loss with regular use.

Part it on the left today? Or on the right. Good dilemmas.

Once a day


Take finasteride as prescribed by your doctor. Just keep in mind there aren’t additional benefits from taking it more than once a day.

What is Finasteride?


Finasteride is an FDA approved medication that treats hair loss in men by blocking DHT (dihydrotestosterone). DHT is a hormone derived from testosterone thought to be the reason why many guys experience hair loss.

Consistency is key


If you miss a day, it’s all good, just skip it and get back on your game the next day. Just don’t take two doses to make up for it.

Backed by science


Finasteride stops testosterone from converting into DHT, the androgen that shrinks hair follicles which leads to hair loss.

It’s rare


Side effects may occur with any prescription medicine. Some men may experience a reaction to Finasteride. Talk to your doctor if you experience any side effects while taking it.

Finasteride Effective in Preventing Prostate Cancer

Cancer Prevention Trial (PCPT), finasteride (Proscar), an agent commonly used to treat lower urinary tract problems and baldness in men, was safe and effective in reducing the risk of prostate cancer. The findings were recently published published in the New England Journal of Medicine.1

“Finasteride is safe, inexpensive, and effective as a preventive strategy for prostate cancer,” principal investigator Ian Thompson, Jr, MD, chair of SWOG’s Genitourinary Cancer committee, and president of CHRISTUS Santa Rosa Hospital Medical Center, said in a press release. “Doctors should share these results with men who get regular prostate-specific antigen (PSA) tests that screen for the presence of prostate cancer. The drug will have its greatest effect in this group of men.”

The initial SWOG Cancer Research Network PCPT trial, which was funded by the National Cancer Institute, first opened for enrollment in January 1993. In the trial, 18,882 men aged ≥55 years with a normal digital rectal exam and a PSA level ≤3.0 ng/ml were randomized to receive 5 mg of finasteride daily (n = 4368) or placebo (n = 4692) for 7 years.

Patients were excluded from the first analysis if they had a prior diagnosis of prostate cancer (n = 2), had failed to complete the study due to early termination (n = 2585), died (n = 1123), refused end-of-study biopsy (n = 3927), were lost to follow-up (n = 1256), had data that was still in review (n = 64), or had an end-of-study biopsy after randomization cut-off (n = 865).

Of the 9060 men who were included in the first analysis, prostate cancer was detected in 18.4% of men (n = 803) in the finasteride arm and 24.4% of men (n = 1147) in the placebo arm, resulting in a 24.8% reduction in the prevalence of prostate cancer over the 7-year span (HR, 0.75; 95% CI, 18.6%-30.6%; P<.001).

The percentage of men who experienced sexual adverse events was higher in the finasteride arm, whereas men in the placebo arm were more likely to experience urinary symptoms. Notably, higher-grade tumors with a Gleason score ≥7 were more commonly observed in men in the finasteride group (37%) versus those in the placebo group (22.2%).2 These findings raised concerns over an increased risk of developing high-grade disease, which prompted the FDA in 2011 to issue guidance against its use for the prevention of prostate cancer.

However, subsequent analysis from the PCPT trial spanning an additional year in length revealed no significant difference in the rates of overall survival after a diagnosis of prostate cancer. Among the entire study population, prostate cancer was identified in 10.5% of men (989/9423) in the finasteride arm and 14.9% of men (1412/9457) in the placebo arm (HR, 0.70; 95% CI, 0.65-0.76; <.001). Of those diagnoses, 3.5% (n = 333) and 3.0% (n = 286) of patients were classified as having high-grade disease in the finasteride and placebo groups, respectively (relative risk, 1.17; 95% CI, 1.00-1.37; = .05).3

In this analysis, 5034 deaths occurred—2538 of which were reported in the finasteride group, while 2496 occurred in the placebo group. The 10-year survival rates were 83.0% in the finasteride arm versus 80.9% in the placebo arm for men with low-grade disease and 73.0% versus 73.6%, respectively, for men with high-grade disease. The 15-year survival rates were 78.0% and 78.2% with finasteride and placebo, respectively.

Researchers then paired study participants to the National Death Index, a database of death records overseen by the US Centers for Disease Control Prevention. At a median follow-up of 18.4 years, there were 3048 deaths in the finasteride arm and 2979 deaths in the placebo arm. Forty-two deaths in the finasteride arm and 56 deaths in the placebo arm were attributed to prostate cancer; of those deaths, 18 in the finasteride arm and 20 in the placebo arm were classified by a Gleason score ≥7, revealing no evidence of increased risk of high-grade prostate cancer with finasteride.

“There are significant negative consequences to patients’ health and quality of life that can result from prostate cancer treatment, as well as to their finances and their peace of mind,” said Thompson. “If we can save people from surgeries, and scores of examinations and tests, and spare them from living for years with fear, we should. The best-case scenario for patients is prevention, and this trial has found an inexpensive medication that gets us there.”


  1. Goodman PJ, Tangen CM, Darke AK, et al. Long-term effects of finasteride on prostate cancer mortality. N Engl J Med. 2019;380(4):393-394. doi: 10.1056/NEJMc1809961.
  2. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. doi: 10.1056/NEJMoa030660.
  3. Thompson IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603-610. doi: 10.1056/NEJMoa1215932.


Submit your review

Create your own review

Average rating:  
 1 reviews
 by ignacio ferera

I don't know what all the fuss is about. I've been taking Finasteride for 2 years, and I have had zero side effects. Another friend of mine has been taking Proscar for 14 years straight, and he hasn't had any problems whatsoever.